BridgeBio Pharma (BBIO) Competitors $48.91 -0.11 (-0.22%) Closing price 04:00 PM EasternExtended Trading$48.88 -0.03 (-0.07%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BBIO vs. ONC, BNTX, INSM, SMMT, TEVA, GMAB, ASND, RDY, VTRS, and QGENShould you be buying BridgeBio Pharma stock or one of its competitors? The main competitors of BridgeBio Pharma include BeOne Medicines (ONC), BioNTech (BNTX), Insmed (INSM), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), and QIAGEN (QGEN). These companies are all part of the "pharmaceutical products" industry. BridgeBio Pharma vs. Its Competitors BeOne Medicines BioNTech Insmed Summit Therapeutics Teva Pharmaceutical Industries Genmab A/S Ascendis Pharma A/S Dr. Reddy's Laboratories Viatris QIAGEN BridgeBio Pharma (NASDAQ:BBIO) and BeOne Medicines (NASDAQ:ONC) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations. Which has more risk & volatility, BBIO or ONC? BridgeBio Pharma has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Do analysts prefer BBIO or ONC? BridgeBio Pharma currently has a consensus price target of $61.35, indicating a potential upside of 25.44%. BeOne Medicines has a consensus price target of $330.89, indicating a potential upside of 5.88%. Given BridgeBio Pharma's higher probable upside, equities analysts clearly believe BridgeBio Pharma is more favorable than BeOne Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 3.00BeOne Medicines 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BBIO or ONC more profitable? BeOne Medicines has a net margin of -3.89% compared to BridgeBio Pharma's net margin of -329.25%. BridgeBio Pharma's return on equity of 0.00% beat BeOne Medicines' return on equity.Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-329.25% N/A -85.69% BeOne Medicines -3.89%-1.22%-0.72% Does the media refer more to BBIO or ONC? In the previous week, BridgeBio Pharma had 6 more articles in the media than BeOne Medicines. MarketBeat recorded 17 mentions for BridgeBio Pharma and 11 mentions for BeOne Medicines. BridgeBio Pharma's average media sentiment score of 0.86 beat BeOne Medicines' score of 0.32 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 10 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in BBIO or ONC? 99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 18.2% of BridgeBio Pharma shares are owned by insiders. Comparatively, 6.6% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better valuation and earnings, BBIO or ONC? BridgeBio Pharma has higher earnings, but lower revenue than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$221.90M42.14-$535.76M-$4.09-11.96BeOne Medicines$3.81B8.99-$644.79M-$1.73-180.64 SummaryBridgeBio Pharma beats BeOne Medicines on 11 of the 15 factors compared between the two stocks. Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BBIO vs. The Competition Export to ExcelMetricBridgeBio PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.35B$4.00B$5.76B$9.65BDividend YieldN/A1.23%3.91%4.09%P/E Ratio-11.9611.0430.7825.12Price / Sales42.1411.76457.76157.42Price / CashN/A7.2725.2228.45Price / Book-6.343.169.365.94Net Income-$535.76M-$109.62M$3.26B$265.56M7 Day Performance-0.37%5.08%1.83%0.95%1 Month Performance5.16%23.52%3.69%2.47%1 Year Performance94.32%33.58%28.88%20.24% BridgeBio Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BBIOBridgeBio Pharma4.7479 of 5 stars$48.91-0.2%$61.35+25.4%+100.9%$9.35B$221.90M-11.96400ONCBeOne Medicines0.6443 of 5 stars$289.75+0.5%$330.89+14.2%N/A$31.58B$3.81B0.0011,000BNTXBioNTech1.6248 of 5 stars$109.26-2.1%$135.91+24.4%+32.1%$26.84B$2.98B-68.296,772Analyst RevisionINSMInsmed4.0992 of 5 stars$112.89+3.0%$112.71-0.2%+67.0%$23.16B$363.71M-19.771,271SMMTSummit Therapeutics2.3402 of 5 stars$28.25-1.4%$34.67+22.7%+126.6%$21.28B$700K0.00110News CoverageAnalyst DowngradeGap DownTEVATeva Pharmaceutical Industries3.5997 of 5 stars$16.41+0.3%$24.71+50.6%-1.0%$18.78B$16.54B6.5536,830News CoveragePositive NewsGMABGenmab A/S3.8673 of 5 stars$21.08-1.6%$37.80+79.3%-13.1%$13.75B$3.12B12.532,682Positive NewsAnalyst RevisionASNDAscendis Pharma A/S2.0562 of 5 stars$195.97+2.3%$239.80+22.4%+39.8%$11.71B$393.54M-37.981,017Analyst ForecastRDYDr. Reddy's Laboratories2.8344 of 5 stars$13.81+0.0%$16.95+22.8%-12.8%$11.52B$3.81B20.9227,811News CoverageVTRSViatris2.0018 of 5 stars$9.86+1.6%$10.40+5.5%-8.8%$11.38B$14.74B4.0232,000High Trading VolumeQGENQIAGEN3.6522 of 5 stars$48.02-0.1%$49.69+3.5%+7.2%$10.68B$1.98B20.485,765News Coverage Related Companies and Tools Related Companies BeOne Medicines Alternatives BioNTech Alternatives Insmed Alternatives Summit Therapeutics Alternatives Teva Pharmaceutical Industries Alternatives Genmab A/S Alternatives Ascendis Pharma A/S Alternatives Dr. Reddy's Laboratories Alternatives Viatris Alternatives QIAGEN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BBIO) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access